Heidelberg Pharma AG (ETR:HPHA)

PRESS RELEASE

published on 08/28/2025 at 03:50, 1 year ago

EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
Heidelberg Pharma's partner Telix Pharmaceuticals faces delays in TLX250-CDx FDA approval. USD 70 million payment from HealthCare Royalty postponed. Current cash reach until Q1 2026

FDA Approval Heidelberg Pharma HealthCare Royalty Telix Pharmaceuticals TLX250-CDx
BRIEF

published on 07/10/2025 at 07:08, 1 year 1 month ago

Heidelberg Pharma's Promising Mid-Year 2025 Developments

Leadership Changes Royalty Agreement Financial Developments HDP-101 Trials HDP-102 Introduction
BRIEF

published on 07/10/2025 at 07:08, 1 year 1 month ago

Développements prometteurs de Heidelberg Pharma pour la mi-année 2025

Changements De Direction Évolution Financière Accord De Redevances Essais HDP-101 Présentation Du HDP-102
PRESS RELEASE

published on 07/10/2025 at 07:03, 1 year 1 month ago

Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
Heidelberg Pharma AG reports on positive first half-year 2025 business performance including advancements in ATAC candidates HDP-101 and HDP-102. Financial figures show promising results in line with planning

Financial Report Clinical Trials HDP-101 Heidelberg Pharma AG ATAC Candidates
BRIEF

published on 05/27/2025 at 08:12, 1 year 3 months ago

Heidelberg Pharma Begins Phase I Study for HDP-102 in Non-Hodgkin Lymphoma

Heidelberg Pharma ADC Technology HDP-102 Non-Hodgkin Lymphoma Phase I Study
BRIEF

published on 05/27/2025 at 08:12, 1 year 3 months ago

Heidelberg Pharma lance une étude de phase I pour le HDP-102 dans le lymphome non hodgkinien

Heidelberg Pharma Technologie ADC HDP-102 Lymphome Non Hodgkinien Étude De Phase I
PRESS RELEASE

published on 05/27/2025 at 08:07, 1 year 3 months ago

Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma
Heidelberg Pharma dosed first patient in Phase I study of Amanitin-based ADC HDP-102 for Non-Hodgkin Lymphoma. ATAC technology targeting CD37. Promising data presented at AACR 2024

Heidelberg Pharma ATAC Technology Amanitin-based ADC Non-Hodgkin Lymphoma Phase I Study
BRIEF

published on 05/15/2025 at 14:36, 1 year 3 months ago

Heidelberg Pharma Announces AGM Results and New Supervisory Board

Supervisory Board Biotech Heidelberg Pharma ADCs AGM 2025
BRIEF

published on 05/15/2025 at 14:36, 1 year 3 months ago

Heidelberg Pharma annonce les résultats de son assemblée générale annuelle et la création d'un nouveau conseil de surveillance

Biotechnologie Conseil De Surveillance Heidelberg Pharma ADC Assemblée Générale Annuelle 2025
PRESS RELEASE

published on 05/15/2025 at 14:31, 1 year 3 months ago

Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board
Heidelberg Pharma AG reports on the results of the Ordinary Annual General Meeting 2025 and the appointment of a new Supervisory Board. Key decisions made include new board members and Dr. Karl Benedikt Biesinger elected as Chairman

Annual General Meeting Supervisory Board Heidelberg Pharma AG ADCs Dr. Karl Benedikt Biesinger

Published on 08/28/2026 at 14:00, 6 hours 57 minutes ago

Lobe Sciences Expands Leadership Team with New CFO Appointment
Published on 08/28/2026 at 13:00, 7 hours 57 minutes ago

Abasca Files NI 43-101 Technical Report, Commences Summer Exploration Program at Loki and Elects to File Semi-annual Interim Financial Statements and Related MD&A
Published on 08/28/2026 at 08:05, 12 hours 52 minutes ago

Caledonia Mining Corporation Plc: Maiden Mineral Resource Estimate at Motapa 379,000 oz Measured and Indicated; 131,000 oz Inferred
Published on 08/28/2026 at 08:05, 12 hours 52 minutes ago

Tocvan Announces New Surface Mineralization in Several Zones at Gran Pilar Gold-Silver Project
Published on 08/28/2026 at 08:00, 12 hours 57 minutes ago

Caledonia Mining Corporation Plc: Blanket Mine Underground Measured and Indicated Mineral Resources Estimate Increases by 22% to 2.18 Million Ounces and Declaration of a Surface Mineral Resource Estimate

View all ACCESSWIRE

Published on 08/28/2026 at 20:42, 14 minutes ago

Aroundtown SA: Release of a capital market information
Published on 08/28/2026 at 19:10, 1 hour 46 minutes ago

Invitation to Professional or Qualified Investors holding Notes to submit offers for Branicks Bridge Notes and VIB Bridge Notes
Published on 08/28/2026 at 18:01, 2 hours 55 minutes ago

CPI Europe announces unaudited results for the first half of 2026
Published on 08/28/2026 at 18:00, 2 hours 56 minutes ago

Highlight Event and Entertainment AG publishes results for the first half of 2026
Published on 08/28/2026 at 18:00, 2 hours 56 minutes ago

Investis successfully issues a fixed rate bond of CHF 100 million

View all EQS

Published on 08/28/2026 at 18:27, 2 hours 29 minutes ago

Droits de vote au 31-07-2026
Published on 08/28/2026 at 18:25, 2 hours 31 minutes ago

Droits de vote au 30-06-2026
Published on 08/28/2026 at 17:45, 3 hours 12 minutes ago

STEF : Droits de vote au 31 07 2026
Published on 08/28/2026 at 06:55, 14 hours 2 minutes ago

Recticel Accelerates Profitable Growth
Published on 08/28/2026 at 06:55, 14 hours 2 minutes ago

Recticel versnelt winstgevende groei

View all LES ECHOS COMFI WIRE

News